Abstract
BACKGROUND: Tumor lysis syndrome (TLS) is a life-threatening complication during the treatment of malignant neoplasia. We sought to describe characteristics and predictors of acute kidney injury (AKI), remission and mortality in high-risk TLS patients. In this retrospective monocentric study, we included all patients with the diagnosis of biological and/or clinical TLS from 2012 to 2018. The primary outcome was the prevalence of AKI during the acute phase of TLS. Secondary outcomes were overall mortality and remission of the underlying malignancy at 1 year. RESULTS: Among 153 patients with TLS, 123 (80.4%) patients experienced AKI and 83 (54.2%) required renal replacement therapy. mSOFA score (OR = 1.15, IC 95% [1.02-1.34]), age (OR = 1.05, IC 95% [1.02-1.08]) and male gender (OR = 6.79, IC 95% [2.59-19.44]) were associated with AKI. Rasburicase use (HR = 2.45, IC 95% [1.17-5.15]) was associated with remission of the underlying malignancy at 1 year. Parameters associated with mortality at 1 year were mechanical ventilation (HR = 1.96, IC 95% [1.02-3.78]), vasopressors (HR = 3.13, IC 95% [1.59-6.15]), age (HR = 1.02, IC 95% [1-1.03]), spontaneous TLS (HR = 1.65, IC 95% [1.01-2.69]) and delay of chemotherapy administration (HR = 1.01, IC 95% [1-1.03]). CONCLUSIONS: AKI is highly prevalent in TLS patients. Rasburicase is associated with better outcomes regarding remission of the underlying malignancy. As rasburicase may be an indirect marker of a high degree of tumor lysis and chemosensitivity, more studies are warranted to confirm the protective role of urate oxidase. Delaying chemotherapy may be deleterious in terms of long-term outcomes.